PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33311577-3	2021	Here we found that background treatment with metformin diminished the SGLT2i-induced reductions in eGFR after 3 months of SGLT2i therapy in patients with type 2 diabetes and hypertension (-2.29 +- 0.90 vs -5.85 +- 1.27 mL/min/1.73 m2 for metformin users (n = 126) and nonusers (n = 97), respectively).	Metformin	45-54	epidermal growth factor receptor	Homo sapiens	99-103	
33311577-3	2021	Here we found that background treatment with metformin diminished the SGLT2i-induced reductions in eGFR after 3 months of SGLT2i therapy in patients with type 2 diabetes and hypertension (-2.29 +- 0.90 vs -5.85 +- 1.27 mL/min/1.73 m2 for metformin users (n = 126) and nonusers (n = 97), respectively).	Metformin	238-247	epidermal growth factor receptor	Homo sapiens	99-103	
33311577-6	2021	Next, we evaluated the interaction between metformin and RASis in the eGFR responses to SGLT2is.	Metformin	43-52	epidermal growth factor receptor	Homo sapiens	70-74	
33311577-7	2021	Under no background treatment with RASis, metformin abrogated the eGFR response to SGLT2is, but this response was preserved when RASis had been given along with metformin (decreases of 0.75 +- 1.28 vs. 4.60 +- 1.15 mL/min/1.73 m2 in eGFR, p = 0.028).	Metformin	42-51	epidermal growth factor receptor	Homo sapiens	66-70	
33311577-9	2021	In conclusion, metformin blunts the SGLT2i-induced decrease in eGFR, but coadministration of RASis ameliorates this response.	Metformin	15-24	epidermal growth factor receptor	Homo sapiens	63-67